BETA DRUGS LIMITED

BDL/PKL/SEC/2026-27
22nd October, 2026

To
The Listing Department
National Stock Exchange of India Ltd.
Exchange Plaza, 5th Floor
Plot no. C/l, G Block
Bandra-Kurla Complex, Bandra (E)
Mumbai — 400 051.

SYMBOL-BETA

Sub:- Statement of deviation or variation in the use of proceeds of Preferential Issue for the quarter ended 30th September, 2026.

Ref:- Regulation 32 of the SEBI (Listing Obligations & Disclosures Requirements) Regulations, 2015

Dear Sir/Madam,

With reference to subject matter and pursuant to Regulation 32 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 read with SEBI circular No. CIR/CFD/CMD1/162/2019 dated December 24, 2019, we hereby confirm that during the quarter ended September 30, 2026 there is no deviation or variation in the use of proceeds from the objects stated in the Private Placement Offer cum Application Letter dated November 18, 2024.

A statement of deviation, stating that there is no deviation or variation in the utilisation of these proceeds, duly reviewed by the Audit Committee of the Company and taken on record by the Board of Directors at their respective meetings held on 22nd October, 2026, is attached herewith.

Kindly take the same on record.

Thanking You
Your's faithfully
For Beta Drugs Ltd.

Beta Drugs Limited
Rajni
Company Secretary
ACS - 24684

Rajni Brar
Company Secretary

BETA DRUGS LIMITED

STATEMENT OF DEVIATION OR VARIATION IN UTILIZATION OF FUNDS RAISED UNDER PREFERENTIAL ISSUE	
Name of Listed Entity	Beta Drugs Limited
Mode of Fund Raising	Preferential Issues
Date of Raising Funds	25-11-2024
Amount Raised	Rs 117.01 crores
Report filed for Quarter ended	30-09-2026
Monitoring Agency	Applicable
Monitoring Agency Name, if applicable	Brickwork Ratings India Private Limited
Is there a Deviation / Variation in use of funds raised	No
If yes, whether the same is pursuant to change in terms of a contract or objects, which was approved by the shareholders	Not applicable
If Yes, Date of shareholder Approval	Not applicable
Explanation for the Deviation / Variation	Not applicable
Comments of the Audit Committee after review	No comments
Comments of the auditors, if any	No Comments

CIN No.: L24230HP2005PLC028969
Admin. Office : SCO 184, Sector-5, Panchkula-134 114 Haryana (INDIA) Phone: +91-172-2585481-482-483
Registered Office & Works: Vill. Nandpur, Lodhimajra Road, Tehsil. : Baddi, Distt. Solan, H.P. Phone No. : 01795-236196
Website :- www.betadrugslimited.com **E-Mail :-** info@betadrugslimited.com

BETA DRUGS LIMITED

Objects for which funds have been raised in the Preferential Issue and details of deviation, if any, in the following table:-
(Amount in crores)

No	Original Object	Modified Object, if any	Original Allocation	Modified allocation, if any	Funds Utilised	Amount of Deviation/Variation for the quarter according to applicable object	Remarks if any
1	Facility Upgradation of 100% Subsidiary - Adley Formulations P Ltd.	NA	**8**	NA	**2.25**	NA	No deviation from objects
2	Facility Upgradation of 100% Subsidiary - Adley Lab Ltd.	NA	**5**	NA	**1.35**	NA	No deviation from objects
3	R & D facilty (new setup)	NA	**15**	NA	**0.95**	NA	No deviation from objects
4	Geographical Expansion **4.1** New Registrations **4.2** Audits **4.3** Dossiers costs **4.4** Bioequivalence studies costs	NA	**10**	NA	0.00	NA	No deviation from objects
5	Capital Expenditure (Manufacturing- new setup)	NA	**44**	NA	**9.52**	NA	No deviation from objects
6	Capital Investment (including capital acquisitions)	NA	**20**	NA	**19.94**	NA	No deviation from objects
7	General Corporate	NA	**15**	NA	**13.36**	NA	No deviation from objects
	TOTAL		**117**		**47.37**		

For Beta Drugs Limited

Beta Drugs Limited
Company Secretary
ACS - 24684

Rajni Brar
Company Secretary &Compliance Officer

CIN No.: L24230HP2005PLC028969
Admin. Office : SCO 184, Sector-5, Panchkula-134 114 Haryana (INDIA) Phone: +91-172-2585481-482-483
Registered Office & Works: Vill. Nandpur, Lodhimajra Road, Tehsil. : Baddi, Distt. Solan, H.P. Phone No. : 01795-236196
Website :- www.betadrugslimited.com | **E-Mail :-** info@betadrugslimited.com